Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
When do you consider disease modifying therapy in radiographically isolated syndrome?
Does reclassification of RIS as MS in upcoming McDonald Criteria change this decision for you?
Related Questions
What are red flags in an evaluation for possible multiple sclerosis that should prompt workup for genetic/inherited conditions?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
What therapy do you recommend in situations where IV steroids and IVIg do not help patients with GABA-A encephalitis?
How do you handle medication management for patients on immunosuppressive therapy who are lost to follow-up?
At what degree of lymphopenia do you switch/discontinue dimethyl fumarate in patients with multiple sclerosis?
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?
For patients on anti-CD20 therapy for MS without frequent/opportunistic infections, are there serum IgG levels or ALC levels in which you pause or change therapy due to low levels?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?